The first biosimilar developed by Dong-A ST has made over KRW 10 billion in exports for 2 consecutive years. The cumulative export sales amount of the drug reached KRW 35.6 billion only 3 years after the drug entered the Japanese market.

According to Dong-A ST on the 1st, the overseas sales of ‘Darbepoetin-α’ last year recorded KRW 13.3 billion, a 6.4% increase from KRW 12.5 billion in 2021.

Darbepoetin-α is a biosimilar of the second-generation anemia treatment ‘Nesp (darbepoetin-α)’ that was co-developed by Amgen and Kyowa Kirin. The erythropoietin (EPO) in the drug accelerates red blood cell production by stimulating the erythroblasts and is used to treat chronic kidney disease or